Eva Fortea Verdejo
Stock Analyst at Wells Fargo
(4.71)
# 169
Out of 5,006 analysts
18
Total ratings
73.33%
Success rate
29.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eva Fortea Verdejo
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRUS Merus | Downgrades: Equal-Weight | $95 → $97 | $94.27 | +2.90% | 5 | Sep 30, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Overweight | $42 → $45 | $38.29 | +17.52% | 3 | Sep 25, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $67 → $70 | $46.58 | +50.28% | 1 | Sep 11, 2025 | |
| XNCR Xencor | Maintains: Overweight | $33 → $27 | $11.79 | +129.01% | 3 | Aug 7, 2025 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $26 → $25 | $14.48 | +72.65% | 3 | Aug 7, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $44 | $27.49 | +60.06% | 1 | Jun 26, 2025 | |
| BCAX Bicara Therapeutics | Upgrades: Equal-Weight | $8 | $18.03 | -55.63% | 2 | May 23, 2025 |
Merus
Sep 30, 2025
Downgrades: Equal-Weight
Price Target: $95 → $97
Current: $94.27
Upside: +2.90%
Kiniksa Pharmaceuticals International,
Sep 25, 2025
Maintains: Overweight
Price Target: $42 → $45
Current: $38.29
Upside: +17.52%
Revolution Medicines
Sep 11, 2025
Maintains: Overweight
Price Target: $67 → $70
Current: $46.58
Upside: +50.28%
Xencor
Aug 7, 2025
Maintains: Overweight
Price Target: $33 → $27
Current: $11.79
Upside: +129.01%
Arcus Biosciences
Aug 7, 2025
Maintains: Overweight
Price Target: $26 → $25
Current: $14.48
Upside: +72.65%
IDEAYA Biosciences
Jun 26, 2025
Initiates: Overweight
Price Target: $44
Current: $27.49
Upside: +60.06%
Bicara Therapeutics
May 23, 2025
Upgrades: Equal-Weight
Price Target: $8
Current: $18.03
Upside: -55.63%